These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8108596)

  • 41. Low molecular weight heparin--does it favourably affect lipid levels?
    Stenvinkel P
    Nephrol Dial Transplant; 1995; 10(1):16-8. PubMed ID: 7724021
    [No Abstract]   [Full Text] [Related]  

  • 42. Heparin usage in chronic hemodialysis.
    Lewis LM
    Nephrol Nurse; 1981; 3(2):33, 47. PubMed ID: 6907680
    [No Abstract]   [Full Text] [Related]  

  • 43. False rise of starch-iodine determined amylase values caused by heparin treatment during haemodialysis.
    Pasternack A; Stenman UH
    Clin Chim Acta; 1975 Dec; 65(2):213-21. PubMed ID: 1183054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipoprotein(a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration.
    Fiorini F; Masturzo P; Mij M; Bertolini S
    Nephron; 1995; 70(4):500-1. PubMed ID: 7477660
    [No Abstract]   [Full Text] [Related]  

  • 45. Lipoprotein lipase does not affect lipoprotein (a) levels in normotriglyceridemic patients.
    Santos RD; Vinagre C; Maranhão RC
    Int J Cardiol; 1995 Jun; 50(1):79-81. PubMed ID: 7558469
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hemodialysis without heparin. The effect on hemocoagulation parameters].
    Charvát J; Kaslíková J; Bláha J; Spánková H; Mlejnková M; Harosová H; Adamová Z
    Cas Lek Cesk; 1986 Dec; 125(49):1508-10. PubMed ID: 3802141
    [No Abstract]   [Full Text] [Related]  

  • 47. The effect of continuous heparin infusion for one year on serum cholesterol and triglyceride concentrations in the dog.
    Blackshear PJ; Rohde TD; Varco RL; Buchwald H
    Atherosclerosis; 1977 Jan; 26(1):23-7. PubMed ID: 836345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I:A-II in healthy volunteers.
    Neele DM; Buytenhek R; Staels B; Dallongeville J; Wallnöfer AE; Kooistra T; Princen HM
    J Intern Med; 1999 Jul; 246(1):120-2. PubMed ID: 10447235
    [No Abstract]   [Full Text] [Related]  

  • 49. Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis.
    Barbagallo CM; Averna MR; Scafidi V; Galione A; Notarbartolo A
    Nephron; 1992; 62(4):471-2. PubMed ID: 1300447
    [No Abstract]   [Full Text] [Related]  

  • 50. [Complications of extracorporeal hemosorption and their prevention].
    Mazur LI; Nikolaĭchik VV; Astapenko VG; Ostapenko VA
    Vestn Khir Im I I Grek; 1983 Jun; 130(6):114-9. PubMed ID: 6612925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are the increased Lp(a) levels in hemodialysis patients related to glucose intolerance and hemodialysis duration?
    Elisaf M; Siamopoulos KC
    Nephron; 1996; 74(3):623-4. PubMed ID: 8938695
    [No Abstract]   [Full Text] [Related]  

  • 52. Low-molecular-weight heparin and lipoprotein(a) in patients with chronic renal failure.
    Sagripanti A; Cozza V; Barsotti G
    Nephron; 1997; 76(1):123-4. PubMed ID: 9171316
    [No Abstract]   [Full Text] [Related]  

  • 53. Enzymatic extracorporeal deheparinization: effects of sub-chronic exposure to heparin fragments.
    Larsen AK; Hetelekidis S; Langer R
    Trans Am Soc Artif Intern Organs; 1984; 30():298-302. PubMed ID: 6533900
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway.
    Di Nisio M; ten Wolde M; Meijers JC; Buller HR
    J Thromb Haemost; 2005 Sep; 3(9):2123-5. PubMed ID: 16102130
    [No Abstract]   [Full Text] [Related]  

  • 55. [Total heparinization in hemodialysis].
    Trikashnyĭ AA
    Eksp Khir Anesteziol; 1971; 16(1):49-51. PubMed ID: 5136518
    [No Abstract]   [Full Text] [Related]  

  • 56. Heparin activity during hemodialysis.
    Simons O
    Clin Nephrol; 1984 Apr; 21(4):247. PubMed ID: 6733990
    [No Abstract]   [Full Text] [Related]  

  • 57. [Heparin and lipoprotein(a). Observations during hemodialysis].
    Salvini P; Maddaloni E; Levi della Vida MV; Parma A; Corpetti MG; Di Lorenzo M
    Recenti Prog Med; 1993 Dec; 84(12):828-33. PubMed ID: 8108596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Nassiri AA; Hakemi MS; Soulati M; Marashian M; Rahbar K; Azizi F
    Iran J Kidney Dis; 2009 Jul; 3(3):162-7. PubMed ID: 19617666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.